In this context, it is possible that enhancement of BIM expression or activation of its downstream targets may be a promising strategy for the treatment of EGFR-mutant NSCLC, particularly in the context of mutations conferring secondary resistance to TKI inhibitors. The gene discussed is BCL2L11; the disease is non-small cell lung carcinoma.